ASTHMA
MCID: AST005
MIFTS: 81

Asthma (ASTHMA)

Categories: Genetic diseases, Immune diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Asthma

MalaCards integrated aliases for Asthma:

Name: Asthma 58 39 12 77 54 76 76 38 30 56 6 44 45 15 17 74 3 64 64
Chronic Obstructive Asthma 12 56 17 74
Asthma, Susceptibility to 58 30 6 41
Asthma, Diminished Response to Antileukotriene Treatment in 58 13 6
Bronchial Hyperreactivity 12 56 74
Asthma, Nocturnal, Susceptibility to 58 6
Asthma, Protection Against 58 6
Chronic Obstructive Asthma with Acute Exacerbation 12
Chronic Obstructive Asthma with Status Asthmaticus 12
Asthma-Related Traits, Susceptibility to 58
Asthma, Exercise-Induced 74
Exercise Induced Asthma 12
Exercise-Induced Asthma 12
Asthma Exercise-Induced 56
Asthma-Related Traits 58
Asthma, Bronchial 58
Asthma, Nocturnal 58
Bronchial Asthma 76

Characteristics:

OMIM:

58
Inheritance:
autosomal dominant vs. multifactorial


Classifications:



External Ids:

Disease Ontology 12 DOID:2841
OMIM 58 600807
KEGG 38 H00079
ICD9CM 36 493 493.9
MeSH 45 D001249
NCIt 51 C28397
SNOMED-CT 69 21341004
SNOMED-CT via HPO 70 195967001 991000119106

Summaries for Asthma

MedlinePlus : 44 Asthma is a chronic disease that affects your airways. Your airways are tubes that carry air in and out of your lungs. If you have asthma, the inside walls of your airways become sore and swollen. That makes them very sensitive, and they may react strongly to things that you are allergic to or find irritating. When your airways react, they get narrower and your lungs get less air. Symptoms of asthma include Wheezing Coughing, especially early in the morning or at night Chest tightness Shortness of breath Not all people who have asthma have these symptoms. Having these symptoms doesn't always mean that you have asthma. Your doctor will diagnose asthma based on lung function tests, your medical history, and a physical exam. You may also have allergy tests. When your asthma symptoms become worse than usual, it's called an asthma attack. Severe asthma attacks may require emergency care, and they can be fatal. Asthma is treated with two kinds of medicines: quick-relief medicines to stop asthma symptoms and long-term control medicines to prevent symptoms. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Asthma, also known as chronic obstructive asthma, is related to allergic asthma and intrinsic asthma, and has symptoms including coughing, shortness of breath and recurring periods of wheezing (a whistling sound while breathing). An important gene associated with Asthma is ADRB2 (Adrenoceptor Beta 2), and among its related pathways/superpathways are Asthma and Allograft rejection. The drugs Accolate and Advair have been mentioned in the context of this disorder. Affiliated tissues include Lung, lung and testes, and related phenotypes are asthma and immune system

Disease Ontology : 12 A bronchial disease that is characterized by chronic inflammation and narrowing of the airways, which is caused by a combination of environmental and genetic factors. The disease has symptom recurring periods of wheezing (a whistling sound while breathing), has symptom chest tightness, has symptom shortness of breath, has symptom mucus production and has symptom coughing. The symptoms appear due to a variety of triggers such as allergens, irritants, respiratory infections, weather changes, exercise, stress, reflux disease, medications, foods and emotional anxiety.

NIH Rare Diseases : 54 Asthma is a breathing disorder that affects the airways. People with this condition experience recurrent swelling and narrowing of the airways of the lungs which is associated with wheezing, shortness of breath, chest tightness, and coughing. Most affected people have episodes of symptoms ("asthma attacks") followed by symptom-free periods; however, some may experience persistent shortness of breath in between attacks. Asthma is considered a complex or multifactorial condition that is likely due to a combination of multiple genetic, environmental, and lifestyle factors. Many people with asthma have a personal or family history of allergies, such as hay fever or eczema. Having a family member with asthma is associated with an increased risk of developing the condition. Treatment generally includes various medications, both to prevent asthma attacks and to provide quick relief during an attack.

OMIM : 58 Bronchial asthma is the most common chronic disease affecting children and young adults. It is a complex genetic disorder with a heterogeneous phenotype, largely attributed to the interactions among many genes and between these genes and the environment. Asthma-related traits include clinical symptoms of asthma, such as coughing, wheezing, and dyspnea; bronchial hyperresponsiveness (BHR) as assessed by methacholine challenge test; serum IgE levels; atopy; and atopic dermatitis (Laitinen et al., 2001; Illig and Wjst, 2002; Pillai et al., 2006). See 147050 for information on the asthma-associated phenotype atopy. (600807)

CDC : 3 Asthma is a disease that affects your lungs. It causes repeated episodes of wheezing, breathlessness, chest tightness, and nighttime or early morning coughing. Asthma can be controlled by taking medicine and avoiding the triggers that can cause an attack. You must also remove the triggers in your environment that can make your asthma worse.

Novus Biologicals : 57 Asthma is a chronic lung disease that causes inflammation, thickening and narrowing of airways, as well as an overproduction of mucus. More than 300 million people worldwide suffer from asthma. Asthma symptoms include wheezing, shortness of breath, coughing and tightness of the chest. Interleukin 13 (IL-13) is the key effector cytokine in asthma. IL-13 stimulates airway fibrosis via action of matrix metalloproteinases (MMPs) on tumor transforming growth factor beta (TGN-beta), and also promotes epithelial damage, mucus production and an increased concentration of eosinophils. The inflammatory response characteristic of asthma is augmented by the production of IL-13 and other TH2 cytokines.

UniProtKB/Swiss-Prot : 76 Asthma: The most common chronic disease affecting children and young adults. It is a complex genetic disorder with a heterogeneous phenotype, largely attributed to the interactions among many genes and between these genes and the environment. It is characterized by recurrent attacks of paroxysmal dyspnea, with wheezing due to spasmodic contraction of the bronchi.

PubMed Health : 64 About asthma: Asthma (AZ-ma) is a chronic (long-term) lung disease that inflames and narrows the airways. Asthma causes recurring periods of wheezing (a whistling sound when you breathe), chest tightness, shortness of breath, and coughing. The coughing often occurs at night or early in the morning.Asthma affects people of all ages, but it most often starts during childhood. In the United States, more than 25 million people are known to have asthma. About 7 million of these people are children.

Wikipedia : 77 Asthma is a common long-term inflammatory disease of the airways of the lungs. It is characterized by... more...

Related Diseases for Asthma

Diseases related to Asthma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 755)
# Related Disease Score Top Affiliating Genes
1 allergic asthma 35.4 CCL11 IL13 IL5 NPSR1 RNASE3
2 intrinsic asthma 34.6 IL5 RNASE3
3 cough variant asthma 34.5 IL5 RNASE3
4 ige responsiveness, atopic 34.1 ADRB2 IL13 IL5 PLA2G7 RNASE3
5 status asthmaticus 34.1 ADRB2 IL5 RNASE3
6 allergic rhinitis 33.8 ALOX5 CCL11 IL13 IL5 RNASE3
7 dermatitis 33.4 CCL11 IL13 IL5 NPSR1
8 dermatitis, atopic 33.3 CCL11 IL13 IL5 RNASE3 TNF
9 lung disease 33.3 ADRB2 IL13 IL5 RNASE3 TNF
10 pollen allergy 33.2 IL13 IL5 RNASE3
11 allergic hypersensitivity disease 33.1 CCL11 IL13 IL5 RNASE3
12 churg-strauss syndrome 33.1 IL5 RNASE3 TNF
13 esophagitis, eosinophilic, 1 33.0 CCL11 IL13 IL5
14 latex allergy 33.0 IL13 IL5 RNASE3
15 chronic eosinophilic pneumonia 33.0 CCL11 IL5 RNASE3
16 rhinitis 32.8 CCL11 CYSLTR1 IL13 IL5 RNASE3
17 pulmonary disease, chronic obstructive 32.5 ADRB2 CCL11 IL13 RNASE3 TNF
18 bronchitis 32.4 CCL11 IL5 RNASE3 TNF
19 bronchiolitis 32.2 CCL11 IL13 IL5 RNASE3 TNF
20 hypereosinophilic syndrome 32.0 CCL11 IL13 IL5 RNASE3
21 food allergy 31.9 IL13 IL5 RNASE3
22 sinusitis 31.9 CYSLTR1 IL5 RNASE3
23 pneumonia 31.8 CCL11 IL13 IL5 TNF
24 respiratory allergy 31.6 CCL11 IL13 IL5 RNASE3
25 conjunctivitis 31.6 CCL11 IL13 IL5 RNASE3
26 pulmonary eosinophilia 31.5 CCL11 IL13 IL5 RNASE3
27 cytokine deficiency 31.4 IL13 IL5
28 common cold 31.4 CCL11 IL13 IL5 RNASE3
29 eosinophilic pneumonia 31.3 CCL11 IL13 IL5 RNASE3
30 esophagitis 31.3 CCL11 IL13 IL5
31 otitis media 31.2 CCL11 RNASE3 TNF
32 gastroenteritis 31.2 CCL11 IL5 RNASE3 TNF
33 allergic conjunctivitis 31.1 CCL11 IL13 IL5 RNASE3
34 eosinophilic gastroenteritis 31.0 CCL11 IL5 RNASE3
35 strongyloidiasis 31.0 CCL11 IL13 IL5
36 schistosomiasis 31.0 IL13 IL5 RNASE3 TNF
37 keratoconjunctivitis 30.8 CCL11 IL13 IL5 RNASE3 TNF
38 vernal keratoconjunctivitis 30.8 CCL11 IL13 IL5 RNASE3
39 respiratory syncytial virus infectious disease 30.7 IL13 IL5
40 bronchial disease 30.7 ADRB2 ALOX5 CCL11 CYSLTR1 IL13 IL5
41 chronic conjunctivitis 30.5 CCL11 IL13 IL5 RNASE3
42 paranasal sinus disease 30.4 ALOX5 IL13 IL5
43 human immunodeficiency virus type 1 30.2 ALOX5 CCL11 HLA-G TNF
44 ascaris lumbricoides infection 30.1 IL13 IL5
45 asthma, nasal polyps, and aspirin intolerance 12.6
46 asthma-related traits 1 12.5
47 asthma-related traits 2 12.5
48 asthma-related traits 4 12.5
49 asthma-related traits 5 12.4
50 asthma-related traits 7 12.4

Comorbidity relations with Asthma via Phenotypic Disease Network (PDN):


Acute Cystitis Bronchitis
Familial Atrial Fibrillation Heart Disease
Hypertension, Essential Osteoporosis
Respiratory Failure Status Asthmaticus

Graphical network of the top 20 diseases related to Asthma:



Diseases related to Asthma

Symptoms & Phenotypes for Asthma

Human phenotypes related to Asthma:

33
# Description HPO Frequency HPO Source Accession
1 asthma 33 HP:0002099

Symptoms via clinical synopsis from OMIM:

58
Resp:
asthma
airway hyperresponsiveness

Clinical features from OMIM:

600807

Symptoms:

12
  • coughing
  • shortness of breath
  • recurring periods of wheezing (a whistling sound while breathing)
  • chest tightness
  • mucus production

UMLS symptoms related to Asthma:


dyspnea, cyanosis, snoring, wheezing, coughing, sneezing, spasm, expiratory wheeze, labored breathing

MGI Mouse Phenotypes related to Asthma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.36 ADRB2 ALOX5 BRCA2 CCL11 CYSLTR1 HLA-G

Drugs & Therapeutics for Asthma

PubMedHealth treatment related to Asthma: 64

Asthma is a long-term disease that has no cure. The goal of asthma treatment is to control the disease. Good asthma control will:Prevent chronic and troublesome symptoms, such as coughing and shortness of breathReduce your need for quick-relief medicines (see below)Help you maintain good lung functionLet you maintain your normal activity level and sleep through the nightPrevent asthma attacks that could result in an emergency room visit or hospital stayTo control asthma, partner with your doctor to manage your asthma or your child's asthma. Children aged 10 or older—and younger children who are able—should take an active role in their asthma care.Taking an active role to control your asthma involves:Working with your doctor to treat other conditions that can interfere with asthma management.Avoiding things that worsen your asthma (asthma triggers). However, one trigger you should not avoid is physical activity. Physical activity is an important part of a healthy lifestyle. Talk with your doctor about medicines that can help you stay active.Working with your doctor and other health care providers to create and follow an asthma action plan.An asthma action plan gives guidance on taking your medicines properly, avoiding asthma triggers (except physical activity), tracking your level of asthma control, responding to worsening symptoms, and seeking emergency care when needed.Asthma is treated with two types of medicines: long-term control and quick-relief medicines. Long-term control medicines help reduce airway inflammation and prevent asthma symptoms. Quick-relief, or "rescue," medicines relieve asthma symptoms that may flare up.Your initial treatment will depend on the severity of your asthma. Followup asthma treatment will depend on how well your asthma action plan is controlling your symptoms and preventing asthma attacks.Your level of asthma control can vary over time and with changes in your home, school, or work environments. These changes can alter how often you're exposed to the factors that can worsen your asthma.Your doctor may need to increase your medicine if your asthma doesn't stay under control. On the other hand, if your asthma is well controlled for several months, your doctor may decrease your medicine. These adjustments to your medicine will help you maintain the best control possible with the least amount of medicine necessary.Asthma treatment for certain groups of people—such as children, pregnant women, or those for whom exercise brings on asthma symptoms—will be adjusted to meet their special needs.

FDA approved drugs:

(show all 16)
# Drug Name Active Ingredient(s) 19 Company Approval Date
1
Accolate 19 ZAFIRLUKAST AstraZeneca September 1999|October 1996
2
Advair 19 FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE GlaxoSmithKline August 2000
3
Alvesco 19 CICLESONIDE Nycomed January 2008
4
Arnuity Ellipta 19 FLUTICASONE FUROATE GlaxoSmithKline August 2014
5
Azmacort 19 TRIAMCINOLONE ACETONIDE Rhone Poulenc Rorer November 1996
6
Dulera 19 FORMOTEROL FUMARATE; MOMETASONE FUROATE Merck June 2010
7
Flovent Rotadisk 19 FLUTICASONE PROPIONATE GlaxoSmithKline November 1997
8
Foradil Aerolizer 19 FORMOTEROL FUMARATE Novartis February 2001 (asthma, bronchospasm); September 2001 (COPD)
9
Metaprotereol Sulfate 19 METAPROTERENOL SULFATE Morton Grove Pharmaceuticals March 1997
10
Nucala 19 MEPOLIZUMAB GlaxoSmithKline November 2015
11
Qvar 19 BECLOMETHASONE DIPROPIONATE Ivax May 2002
12
Rayos 19 PREDNISONE Horizon Pharma July of 2012
13
Serevent 19 SALMETEROL XINAFOATE GlaxoSmithKline September 1997
14
Singulair 19 MONTELUKAST SODIUM Merck February 1998
15
Xolair 19 OMALIZUMAB Genentech June 2003
16
Zyflo 19 ZILEUTON Abbott Laboratories January 1997

Drugs for Asthma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1188)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Budesonide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51333-22-3 63006 5281004
2
Nitric Oxide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 10102-43-9 145068
3
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53-03-2 5865
4
Fluticasone Approved, Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 90566-53-3 62924
5
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 93-14-1 3516
6
Pseudoephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 90-82-4 7028
7
Ephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 299-42-3 9294
8
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 2921-57-5
9
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7487-88-9 24083
10
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 83-43-2 6741
11
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 302-25-0
12
Ipratropium Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 60205-81-4, 22254-24-6 43232 657309
13
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-24-8 5755
14
Montelukast Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 158966-92-8 5281040
15
Procaterol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 72332-33-3 688561
16
Midazolam Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59467-70-8 4192
17
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
18
tannic acid Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1401-55-4
19
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 437-38-7 3345
20
Remifentanil Approved Phase 4,Not Applicable 132875-61-7 60815
21
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Not Applicable 113775-47-6 68602 5311068
22
Cisatracurium Approved Phase 4,Not Applicable 96946-41-7
23
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2078-54-8 4943
24
Etomidate Approved Phase 4,Phase 3,Not Applicable 33125-97-2 36339 667484
25
Atracurium Approved, Experimental, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 64228-79-1 47319
26
Omalizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 242138-07-4
27
Lansoprazole Approved, Investigational Phase 4,Phase 3,Phase 2 103577-45-3 3883
28
Dexlansoprazole Approved, Investigational Phase 4,Phase 3,Phase 2 138530-94-6, 103577-45-3 9578005
29
mometasone furoate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83919-23-7
30
Terbutaline Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23031-25-6 5403
31
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-61-7 60961
32
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-45-6 774
33
Xylometazoline Approved, Investigational Phase 4,Phase 3,Not Applicable 526-36-3 5709
34
Azelastine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58581-89-8 2267
35
Capsaicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 404-86-4 1548943
36
Racepinephrine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 329-65-7 838
37
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 51-43-4 5816
38 Strawberry Approved Phase 4
39
Clavulanate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 58001-44-8 5280980
40
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 26787-78-0 33613
41
Mannitol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 69-65-8 453 6251
42
Cetirizine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 83881-51-0 2678
43
Cilostazol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 73963-72-1 2754
44
Betamethasone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 378-44-9 9782
45
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-78-2 2244
46
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 137-58-6 3676
47
Bupivacaine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 2180-92-9, 38396-39-3 2474
48
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 57-27-2 5288826
49
Ketorolac Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 66635-83-4, 74103-06-3 3826
50
Ropivacaine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 84057-95-4 71273 175805

Interventional clinical trials:

(show top 50) (show all 7253)
# Name Status NCT ID Phase Drugs
1 Assessing Decision Maker Tools for Asthma: the Asthma APGAR Unknown status NCT01446315 Phase 4
2 Optimization of Inhaled Corticosteroid Treatment in Adult Patients With Asthma Guided by Exhaled NO Measurement at Home Unknown status NCT01783132 Phase 4
3 Efficacy and Safety of Activation Energy Serum (AES) Versus Placebo in Persistent Asthma. Unknown status NCT01939951 Phase 4
4 Effect of Vitamin D Supplementation on the Control of Asthma in Children at a South African Academic Hospital Unknown status NCT02053402 Phase 4 Vitamin D
5 Vitamin D for the Treatment of Severe Asthma Unknown status NCT00712205 Phase 4 Placebo;Calcitriol
6 Low Exhaled NO and ICS in Suspected Asthma Unknown status NCT02771717 Phase 4 Budesonide (Pulmicort);Placebo - dummy inhaler
7 A Pilot Study Involving an Asthma Management Program for Inner-city Early Head Start Children Unknown status NCT00624429 Phase 4 Budesonide respules
8 Inflammatory, Functional and Image Composite Measure to Define Asthma Control Unknown status NCT00597064 Phase 4 prednisone
9 Assessment of Utility of Exhaled Nitric Oxide Measurement for Treatment Monitoring in Children With Asthma Unknown status NCT00500253 Phase 4
10 Fluticasone/Salmeterol (FP/SM) Versus Double the Dose Fluticasone (FP) in Patients With Mild to Moderate Asthma Unknown status NCT00830505 Phase 4 fluticasone/ salmeterol;fluticasone
11 Evaluation of Efficacy of House Dust Mite Immunotherapy in Children With Bronchial Asthma Unknown status NCT00496574 Phase 4
12 Effects of Su-Huang Antitussive Capsule on Cough Variant Asthma Unknown status NCT01584804 Phase 4 Su-Huang antitussive capsule;Sugar pill
13 Nebulized Magnesium Sulfate as an Adjunct to Standard Therapy in Asthma Exacerbation Unknown status NCT02584738 Phase 4 Nebulized Magnesium Sulfate;Nebulized isotonic saline;Nebulized Salbutamol;Ipratropium bromide;Methylprednisolone or Prednisolone
14 Effects of Leukotriene Modulator Montelukast on Cough Variant Asthma Unknown status NCT01404013 Phase 4 ICS/LABA;Montelukast;ICS/LABA and Montelukast
15 Efficacy and Safety Study of Procaterol Hydrochloride to Treat Patients With Cough Variant Asthma (CVA) Unknown status NCT01170429 Phase 4 Procaterol hydrochloride;Meptin placebo
16 Effect of Dexmedetomidine on Levels of Plasma Inflammatory Factor in Asthma Patients Undergoing General Anesthesia Unknown status NCT02289391 Phase 4 Anesthesia induction;Anesthesia maintenance;Assisted anesthesia
17 Study to Assess the Efficacy and Safety of Omalizumab Treatment on ICS Reduction for Severe IgE-mediated Asthma Unknown status NCT01912872 Phase 4 Omalizumab;Budesonide;Formoterol
18 Assessment of Sublingual Immunotherapy in Children Allergic to House Dust Mites Unknown status NCT01052610 Phase 4 sublingual house dust mites allergen extract;placebo in sublingual applicator
19 Treatment Efficacy of Budesonide/Formoterol in Cough Variant Asthma and Typical Asthma Patients Unknown status NCT02934945 Phase 4 budesonide 160μg/formoterol 4.5μg
20 Effect of Specific Immunotherapy to Dust Mites in Children With Asthma Unknown status NCT00496561 Phase 4
21 Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 Mcg BID Unknown status NCT00235053 Phase 4 fluticasone/salmeterol DISKUS 250/50
22 A Randomized, Double-Blind, Placebo-Controlled Study of Gastroesophageal Reflux Disease Therapy. Unknown status NCT00237068 Phase 4 Lansoprazole; Solutab
23 Extra-fine Formoterol/Beclomethasone in Asthmatic Crisis Unknown status NCT02345993 Phase 4 Extra fine Formoterol/Beclomethasone
24 Comparison of Daily Mometasone Furoate Nasal Spray Alone Versus a Combination With Montelukast for Treatment of Chronic Rhinosinusitis With Asthma After Functional Endoscopic Sinus Surgery Unknown status NCT02110654 Phase 4 Montelukast;mometasone furoate nasal spray
25 Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS) Unknown status NCT00867737 Phase 4 Advair HFA MDI 115/21;Symbicort 160/4.5 pMDI
26 Effect of Xolair on Airway Hyperresponsiveness Unknown status NCT00208234 Phase 4 Omalizumab;Placebo for Omalizumab;omalizumab
27 Sublingual Immunotherapy With House Dust Mite Extract in Asthmatic Children Unknown status NCT00172341 Phase 4 Staloral TM
28 Concentrations of Salmeterol in Blood and Urine Unknown status NCT00914901 Phase 4 inhaled salmeterol
29 Terbutaline Concentrations in Blood and Urine Unknown status NCT00914797 Phase 4 inhaled and oral terbutaline
30 Efficacy of Bronchial Thermoplasty in Korean Unknown status NCT02031263 Phase 4
31 Concentrations of Formoterol in Blood and Urine Unknown status NCT00914654 Phase 4 inhaled formoterol
32 Assessment of Airway Responsiveness and Treatment Efficacy in Asthmatics Unknown status NCT02574975 Phase 4 methacholine;adenosine monophosphate;leukotriene D4;budesonide /formoterol
33 Rapid Onset Action of Salbutamol Versus Formoterol Unknown status NCT00900874 Phase 4 salbutamol;Formoterol
34 The Effect of Bronchodilator on Eosinophilic Bronchitis and Cough Variant Asthma Unknown status NCT02002754 Phase 4 Bambuterol Hydrochloride tablets
35 mRNA Expression as a Biomarker of Omalizumab Response Unknown status NCT01584687 Phase 4
36 A Pilot Efficacy Study of Inhaled Albuterol Delivered With Akita Breath Control Unknown status NCT00385359 Phase 4 Albuterol
37 Treatment of Acute Asthma in ER With Combination of Systemic Steroids and Inhaled Steroids Unknown status NCT00397267 Phase 4 inhalation of corticosteroids
38 Efficacy and Safety of LAIS® Mites Sublingual Tablets Unknown status NCT02277483 Phase 4 LAIS®
39 4"S" - Seasonal Symptoms Suppression Study Unknown status NCT02557269 Phase 4 Xylometazoline - intranasal application;Azelastine - intranasal application;Mometasone furoate - intranasal application;Hydroxyl-propyl-methyl cellulose powder - intranasal application;Bilastine 20 mg;Prednisolone 5 mg
40 Comparative Study of Sinol and Sinol-M in Patients With Congestion Due to Allergic Rhinitis Unknown status NCT00825656 Phase 4 Sinol or Sinol-M nasal spray
41 POLlinosis and Exhaled Breath Temperature Unknown status NCT01785394 Phase 4 5 grass allergen extract
42 Inhaler Lung Deposition in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT01721291 Phase 4 SALBUTAMOL
43 Immunological Mechanisms of Oralair® in Patients With Seasonal Allergic Rhinitis Unknown status NCT02014623 Phase 4 Control
44 Preterm Infant Inhaled Albuterol Dosing Unknown status NCT02447250 Phase 4 Varied albuterol dose response
45 Bronchiolitis All-study, SE-Norway Unknown status NCT00817466 Phase 4 Racemic adrenaline;Isotonic saline
46 Montelukast for Persistent Cough in Young People and Adults Unknown status NCT01279668 Phase 4 Montelukast;Placebo
47 Evaluate the Effects of Formoterol and Beclomethasone Dipropionate Combination Therapy on Small Airways Function Unknown status NCT01466712 Phase 4 Tiotropium + formoterol/beclometasone;tiotropium + placebo
48 Airway Effects of Tiotropium in Patients With COPD Unknown status NCT02683668 Phase 4
49 Can we Help People With the Oral Allergy Syndrome Eat Fresh Fruit? Unknown status NCT01431859 Phase 4
50 Middle Meatal Bacteriology During Acute Respiratory Infection in Children Unknown status NCT00545961 Phase 4 placebo;amoxicillin clavulanate acid

Search NIH Clinical Center for Asthma

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Asthma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Asthma:
Bone marrow-derived mesenchymal stem cells for severe refractory asthma
Embryonic/Adult Cultured Cells Related to Asthma:
Mouse bone marrow-derived mesenchymal stem cells (family) PMIDs: 21653527 20801416

Cochrane evidence based reviews: asthma

Genetic Tests for Asthma

Genetic tests related to Asthma:

# Genetic test Affiliating Genes
1 Asthma, Susceptibility to 30 ADRB2 ALOX5 CCL11 HLA-G HNMT IL13 MUC7 PLA2G7 SCGB3A2 TNF
2 Asthma 30

Anatomical Context for Asthma

MalaCards organs/tissues related to Asthma:

42
Lung, Testes, Heart, T Cells, Skin, Neutrophil, Endothelial
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Asthma:
# Tissue Anatomical CompartmentCell Relevance
1 Lung Trachea Airway Smooth Muscle Cells Affected by disease, potential therapeutic candidate

Publications for Asthma

Articles related to Asthma:

(show top 50) (show all 13303)
# Title Authors Year
1
Preventative tracheal administration of interleukin-27 attenuates allergic asthma by improving the lung Th1 microenvironment. ( 30367458 )
2019
2
Jagged1-expressing adenovirus-infected dendritic cells induce expansion of Foxp3+ regulatory T cells and alleviate T helper type 2-mediated allergic asthma in mice. ( 30418664 )
2019
3
Systemic reaction rates with omalizumab, subcutaneous immunotherapy, and combination therapy in children with allergic asthma. ( 30582494 )
2019
4
Protective effects and active ingredients of Salvia miltiorrhiza Bunge extracts on airway responsiveness, inflammation and remodeling in mice with ovalbumin-induced allergic asthma. ( 30599896 )
2019
5
Therapeutic potential of Morin in Ovalbumin-induced allergic asthma via modulation of SUMF2/IL-13 and BLT2/NF-kB signaling pathway. ( 30605067 )
2019
6
Vitamin D3 in children with allergic asthma in clinical practice. ( 30609318 )
2019
7
S-Allyl cysteine reduces eosinophilic airway inflammation and mucus overproduction on ovalbumin-induced allergic asthma model. ( 30622029 )
2019
8
Allergen challenge increases capsaicin evoked cough responses in allergic asthma. ( 30660644 )
2019
9
A Fusion Protein of Derp2 Allergen and Flagellin Suppresses Experimental Allergic Asthma. ( 30661317 )
2019
10
Relevance of Th2 markers in the assessment and therapeutic management of severe allergic asthma: a real life perspective. ( 30676321 )
2019
11
Time to onset of improvements in Quality of Life from Temperature-controlled Laminar Airflow (TLA) in severe allergic asthma. ( 30704694 )
2019
12
Blockage of sphingosine-1-phosphate receptor 2 (S1P2 ) attenuates allergic asthma in mice. ( 30706444 )
2019
13
Role of transient receptor potential cation channel subfamily V member 1 (TRPV1) on ozone-exacerbated allergic asthma in mice. ( 30708321 )
2019
14
Beneficial effects of rosiglitazone, a peroxisome proliferator-activated receptor-γ agonist, in a mouse allergic asthma model is not associated with the recruitment or generation of Foxp3-expressing CD4+ regulatory T cells. ( 30710547 )
2019
15
Semaphorin 3E inhibits house dust mite-induced angiogenesis in a mouse model of allergic asthma. ( 30711489 )
2019
16
Effect of ginger extract on expression of GATA3, T-bet and ROR-γt in peripheral blood mononuclear cells of patients with Allergic Asthma. ( 30745246 )
2019
17
Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018. ( 30763137 )
2019
18
Reduced Akkermansia muciniphila and Faecalibacterium prausnitzii levels in the gut microbiota of children with allergic asthma. ( 30765132 )
2019
19
Severe Eosinophilic Allergic Asthma Responsive to Mepolizumab After Failure of 2 Consecutive Biologics. ( 30785114 )
2019
20
Efficacy of subcutaneous immunotherapy in a mouse model of Humulus pollen-induced allergic asthma. ( 30787986 )
2019
21
An evaluation of the effects of saffron supplementation on the asthma clinical symptoms and asthma severity in patients with mild and moderate persistent allergic asthma: a double-blind, randomized placebo-controlled trial. ( 30795753 )
2019
22
Suppressive effects of type I angiotensin receptor antagonists, candesartan and irbesartan on allergic asthma. ( 30797786 )
2019
23
IL-4 receptor α blockade prevents sensitization and alters acute and long-lasting effects of allergen-specific immunotherapy of murine allergic asthma. ( 30829405 )
2019
24
The Review of in Vitro and in Vivo Studies over the Glycyrrhizic Acid as Natural Remedy Option for Treatment of Allergic Asthma. ( 30848569 )
2019
25
Real-world effectiveness and safety of omalizumab in patients with uncontrolled severe allergic asthma from the Czech Republic. ( 30858777 )
2019
26
Inhaled delivery of Interferon-lambda restricts epithelial-derived Th2 inflammation in allergic asthma. ( 30861490 )
2019
27
Immunotherapy in Allergic Asthma - 5 year analysis: Is it a curative approach? ( 30862426 )
2019
28
Experimental protocol for development of adjuvant-free murine chronic model of allergic asthma. ( 30880263 )
2019
29
Circulating mast cell progenitors correlate with reduced lung function in allergic asthma. ( 30892731 )
2019
30
Advances in the clinical and mechanism research of pollen induced seasonal allergic asthma. ( 30899604 )
2019
31
Prevalence of allergic bronchopulmonary aspergillosis among patients with severe bronchial asthma in a tertiary care hospital in Northern India. ( 30706871 )
2019
32
Recent Patents in Allergy/Immunology: Use of arginase inhibitors in the treatment of asthma and allergic rhinitis. ( 30865303 )
2019
33
Bronchial asthma triggered by house dust mites in patients with local allergic rhinitis. ( 30887534 )
2019
34
Clinical Response to Subcutaneous Dermatophagoides pteronyssinus Immunotherapy in Children with Allergic Rhinitis and Asthma Is Independent of Sensitization to Blomia tropicalis Allergens. ( 30544116 )
2019
35
Effects of Intranasal Cellulose Powder on Asthma Control in Children With Mild-to-Moderate Perennial Allergic Rhinitis: A Randomized, Placebo-Controlled Trial. ( 30704266 )
2019
36
Prevalence of symptoms of asthma and allergic rhinitis in children in Southern Brazil: a ten-year monitoring study. ( 30720381 )
2019
37
Fast up-dosing with a birch allergoid is safe and well tolerated in allergic rhinitis patients with or without asthma. ( 30730274 )
2019
38
Stepwise approach towards adoption of allergen immunotherapy for allergic rhinitis and asthma patients in daily practice in Belgium: a BelSACI-Abeforcal-EUFOREA statement. ( 30740211 )
2019
39
Prevalence of asthma, allergic rhinitis and eczema in 6-7-year-old schoolchildren from Luanda, Angola. ( 30745247 )
2019
40
Genetic risk of FCRL3 and FCRL5 polymorphisms in children with asthma and allergic rhinitis in a Chinese Han population. ( 30771554 )
2019
41
Evaluating the role of mindfulness in terms of asthma-related outcomes and depression and anxiety symptoms among individuals with asthma. ( 30286606 )
2019
42
Investigating asthma, allergic disease, passive smoke exposure, and risk of rheumatoid. ( 30747496 )
2019
43
MicroRNA-744 Inhibits Proliferation of Bronchial Epithelial Cells by Regulating Smad3 Pathway via Targeting Transforming Growth Factor-β1 (TGF-β1) in Severe Asthma. ( 30903795 )
2019
44
A study of factors related to asthma exacerbation using a questionnaire survey in Niigata Prefecture, Japan. ( 30904001 )
2019
45
Children with severe persistent asthma have disparate peripheral blood and lower airway eosinophil levels. ( 30904479 )
2019
46
Association Between Fungal Spore Exposure in Inner-City Schools and Asthma Morbidity. ( 30904580 )
2019
47
Variables Associated with Emergency Department Utilization by Pediatric Patients with Asthma in a Federally Qualified Health Center. ( 30905027 )
2019
48
The synergistic effects of clopidogrel with montelukast may be beneficial for asthma treatment. ( 30905080 )
2019
49
Effectiveness of an educational program for children and their families on asthma control treatment adherence. ( 30905211 )
2019
50
Montelukast and Neuropsychiatric Events in Children with Asthma: A Nested Case-Control Study. ( 30905424 )
2019